Advertisement
Advertisement

INDV

INDV logo

Indivior Pharmaceuticals, Inc. Common Stock

34.33
USD
Sponsored
-0.12
-0.35%
Feb 06, 15:59 UTC -5
Closed
exchange

After-Market

34.21

-0.12
-0.34%

INDV Earnings Reports

Positive Surprise Ratio

INDV beat 12 of 19 last estimates.

63%

Next Report

Date of Next Report
Feb 26, 2026
Estimate for Q4 25 (Revenue/ EPS)
$311.73M
/
$0.68
Implied change from Q3 25 (Revenue/ EPS)
-0.72%
/
-5.56%
Implied change from Q4 24 (Revenue/ EPS)
+4.26%
/
+112.50%

Indivior Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On Oct 30, 2025, INDV reported earnings of 0.72 USD per share (EPS) for Q3 25, beating the estimate of 0.41 USD, resulting in a 71.47% surprise. Revenue reached 314.00 million, compared to an expected 267.16 million, with a 17.53% difference. The market reacted with a +15.41% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 7 analysts forecast an EPS of 0.68 USD, with revenue projected to reach 311.73 million USD, implying an decrease of -5.56% EPS, and decrease of -0.72% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
For Q3 2025, Indivior Pharmaceuticals, Inc. Common Stock reported EPS of $0.72, beating estimates by 71.47%, and revenue of $314.00M, 17.53% above expectations.
The stock price moved up 15.41%, changed from $25.24 before the earnings release to $29.13 the day after.
The next earning report is scheduled for Feb 26, 2026.
Based on 7 analysts, Indivior Pharmaceuticals, Inc. Common Stock is expected to report EPS of $0.68 and revenue of $311.73M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement